Funding announcement
Curlew Bio Joins MTM's Brisbane Pod
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
News publication
Everything we hold that moleculetomedicine.com published.
Every article we hold from moleculetomedicine.com.
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Deals recorded from moleculetomedicine.com's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Curlew Bio | Accelerator | undated | - |
Companies named in moleculetomedicine.com's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Curlew Bio | 1 | |
| Grey Wolf Therapeutics | 1 | |
| Lucia Bio | Biotech developing Syk inhibitors to treat autoimmune, neuroinflammatory and hematologic … | 1 |
| Molecule to Medicine | 1 | |
| UniQuest Extension Fund | 1 |
Investors named in moleculetomedicine.com's articles, most-covered first.